Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH2 | Q9NR71 | 2/20 | 1.00 |
| ▸ | CETP | P11597 | 4/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849917 | 1.00 | ASAH2 (1.00) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL27013983 | 1.00 | ASAH2 (1.00) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL30145483 | 1.00 | ASAH2 (1.00) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL30654713 | 1.00 | ASAH2 (1.00) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL29967428 | 0.99 | ASAH2 (0.97) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL12227954 | 0.99 | ASAH2 (0.97) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL12252107 | 0.99 | ASAH2 (0.97) | ASAH2CETPTHRBMEN1KMT2A | |
| Sulfuric Acid SCHEMBL10522463 | 0.93 | ASAH2 (0.87) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL18506534 | 0.86 | ASAH2 (0.75) | ASAH2CETPTHRBMEN1KMT2A | |
| SCHEMBL3712341 | 0.85 | ASAH2 (0.74) | ASAH2CETPTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185855-A1 | CONJUGATED OLIGONUCLEOTIDES | UNIVERSITY OF MASSACHUSETTS | 2019-06-20 | — | — | US | disclosed |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | UNIVERSITY OF MASSACHUSETTS | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | DCLRE1B, RTCB, RNASE1 | ASAH2 223/4885CETP 2119/4885THRB 888/4885 |
| US-20190185855-A1 | CONJUGATED OLIGONUCLEOTIDES | DCLRE1B, DCLRE1A, TNNC1 | ASAH2 1198/4885CETP 3532/4885THRB 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.